Piperidine Derivatives and Their Use as Modulators of Chemokine Receptor Activity (Especially CCR5)

Abstract

Compounds of formula (I): wherein L is CH or N; M is CH or N; provided that L and M are not both CH; compositions comprising them, processes for preparing them and their use in medical therapy (for example modulating CCR5 receptor activity in a warm blooded animal).

1 . A compound of formula (I):  
     
       
         
         
             
             
         
       
       wherein  
       L is CH or N; M is CH or N; provided that L and M are not both CH;  
       R 1  is hydrogen, C 1-6  alkyl [optionally substituted by phenyl {which itself optionally substituted by halo, C 1-4  alkyl, C 1-4  alkoxy, cyano, nitro, CF 3 , OCF 3 , (C 1-4  alkyl)C(O)NH, S(O) 2 NH 2 , C 1-4  alkythio, S(O)(C 1-4  alkyl) or S(O) 2 (C 1-4  alkyl)}or heteroaryl {which itself optionally substituted by halo, C 1-4  alkyl, C 1-4  alkoxy, cyano, nitro, CF 3 , (C 1-4  alkyl)C(O)NH, S(O) 2 NH 2 , C 1-4  alkylthio, S(O)(C 1-4  alkyl) or S(O) 2 (C 1-4  alkyl)}], phenyl {optionally substituted by halo, C 1-4  alkyl, C 1-4 alkoxy, cyano, nitro, CF   3 , OCF 3 , (C 1-4  alkyl)C(O)NH, S(O) 2 NH 2 , C 1-4 alkylthio, S(O)(C   1-4  alkyl) or S(O) 2 (C 1-4  alkyl)}, heteroaryl {optionally substituted by halo, C 1-4  alkyl, C 1-4  alkoxy, cyano, nitro, CF 3 , (C 1-4  alkyl)C(O)NH, S(O) 2 NH 2 , C 1-4  alkylthio, S(O)(C 1-4 alkyl) or S(O)   2 (C 1-4 alkyl)}, S(O)   2 R 6 , S(O) 2 NH 10 R 11 , C(O)R 7 , C(O) 2 (C 1-6  alkyl), C(O) 2 (phenyl(C 1-2  alkyl)) or C(O)NHR 7 ; and when M is CH R 1  can also be NHS(O) 2 R 6 , NHS(O) 2 NHR 7 , NHC(O)R 7  or NHC(O)NHR 7 ;  
       R 2  is phenyl or heteroaryl, either of which is optionally substituted by halo, C 1-4  alkyl, C 1-4  alkoxy, S(O) n (C 1-4  alkyl), nitro, cyano or CF 3 ;  
       R 3  is hydrogen or C 1-4  alkyl;  
       R 4  is hydrogen, methyl, ethyl, allyl or cyclopropyl;  
       R 5  is phenyl, heteroaryl, phenylNH, heteroarylNH, phenyl(C 1-2 )alkyl, heteroaryl(C 1-2 )alkyl, phenyl(C 1-2  alkyl)NH or heteroaryl(C 1-2  alkyl)NH; wherein the phenyl and heteroaryl rings of R 5  are optionally substituted by halo, cyano, nitro, hydroxy, C 1-4  alkyl, C 1-4  alkoxy, S(O) k (C 1-4  alkyl), S(O) 2 NR 8 R 9 , NHS(O) 2 (C 1-4 alkyl), NH   2 , NH(C 1-4  alkyl), N(C 1-4  alkyl) 2 , NHC(O)NH 2 , C(O)NH 2 , C(O)NH(C 1-4  alkyl), NHC(O)(C 1-4  alkyl), CO 2 H, CO 2 (C 1-4  alkyl), C(O)(C 1-4  alkyl), CF 3 , CHF 2 , CH 2 F, CH 2 F 3  or OCF 3 ;  
       k, m and n are, independently, 0, 1 or 2;  
       R 6  is C 1-6  alkyl [optionally substituted by halo, C 1-4  alkoxy, phenyl {which itself optionally substituted by halo, C 1-4  alkyl, C 1-4  alkoxy, cyano, nitro, CF 3 , OCF 3 , (C 1-4  alkyl)C(O)NH, S(O) 2 NH 2 , C 1-4  alkylthio, S(O)(C 1-4  alkyl) or S(O) 2 (C 1-4  alkyl)}or heteroaryl {which itself optionally substituted by halo, C 1-4  alkyl, C 1-4  alkoxy, cyano, nitro, CF 3 , (C 1-4  alkyl)C(O)NH, S(O) 2 NH 2 , C 1-4  alkylthio, S(O)(C 1-4  alkyl) or S(O) 2 (C 1-4  alkyl)}], C 3-7  cycloakyl, pyranlyl, phenyl {optionally substituted by halo, C 1-4  alkyl, C 1-4  alkoxy, cyano, nitro, CF 3 , OCF 3 , (C 1-4  alkyl)C(O)NH, S(O) 2 NH 2 , C 1-4  alkylthio, S(O)(C 1-4  alkyl) or S(O) 2 (C 1-4  alkyl)}or heteroaryl {optionally substituted by halo, C 1-4  alkyl, C 1-4  alkoxy, cyano, nitro, CF 3 , OCF 3 , (C 1-4  alkyl)C(O)NH, S(O) 2 NH 2 , C 1-4  alkylthio, S(O)(C 1-4  alkyl) or S(O) 2 (C 1-4  alkyl)};  
       R 7  is hydrogen, C 1-6  alkyl [optionally substituted by halo, C 1-4  alkoxy, phenyl {which itself optionally substituted by halo, C 1-4  alkyl, C 1-4  alkoxy, cyano. nitro, CF 3 , OCF 3 , (C 1-4  alkyl)C(O)NH, S(O) 2 NH 2 , C 1-4  alkylthio, S(O)(C 1-4  alkyl) or S(O) 2 (C 1-4  alkyl)}or heteroaryl {which itself optionally substituted by halo, C 1-4  alkyl, C 1-4  alkoxy, cyano, nitro, CF 3 , (C 1-4  alkyl)C(O)NH, S(O) 2 NH 2 , C 1-4  alkylthio, S(O)(C 1-4  alkyl) or S(O) 2 (C 1-4  alkyl)}], C 3-7  cycloakyl, pyranyl, phenyl {optionally substituted by halo, C 1-4  alkyl, C 1-4  alkoxy, cyano, nitro, CF 3 , OCF 3 , (C 1-4  alkyl)C(O)NH, S(O) 2 NH 2 , C 1-4  alkylthio, S(O)(C 1-4  alkyl) or S(O) 2 (C 1-4  alkyl)}or heteroaryl {optionally substituted by halo, C 1-4  alkyl, C 1-4  alkoxy, cyano, nitro, CF 3 , (C 1-4  alkyl)C(O)NH, S(O) 2 NH 2 , C 1-4  alkylthio, S(O)(C 1-4  alkyl) or S(O) 2 (C 1-4  alkyl)};  
       R 8  and R 9  are, independently, hydrogen or C 1-4  alkyl, or together with a nitrogen or oxygen atom, may join to form a 5- or 6-membered ring which is optionally substituted with C 1-4  alkyl C(O)H or C(O)(C 1-4  alkyl);  
       R 10  and R 11  are, independently, hydrogen or C 1-4  alkyl, or may join to form a 5- or 6-membered ring which is optionally substituted with C 1-4  alkyl or phenyl (wherein the phenyl ring is optionally substituted by halo, cyano, nitro, hydroxy, C 1-4  alkyl, C 1-4  alkoxy, S(O) m C 1-4  alkyl, S(O) 2 NH 2 , S(O) 2 NH(C 1-4  alkyl), S(O) 2 N(C 1-4  alkyl) 2 , NHS(O) 2 (C 1-4  alkyl), NH 2 , NH(C 1-4  alkyl), N(C 1-4  alkyl) 2 , NHC(O)NH 2 , C(O)NH 2 , C(O)NH(C 1-4  alkyl), NHC(O)(C 1-4  alkyl), CO 2 H, CO 2 (C 1-4  alkyl), C(O)(C 1-4  alkyl), CF 3 , CHF 2 , CH 2 F, CH 2 CF 3  or OCF 3 );  
       or a pharmaceutically acceptable salt thereof or a solvate thereof;  
       provided that when R 1  is hydrogen or unsubstituted alkyl, R 4  is hydrogen, methyl or ethyl, L is CH and M is N, then the phenyl or heteroaryl part of R 5  is substituted by one of: S(O) k C 1-4  alkyl, NHC(O)NH 2 , C(O)(C 1-4  alkyl), CHF 2 , CH 2 F, CH 2 CF 3  or OCF 3 , and optionally further substituted by one or more of halo, cyano, nitro, hydroxy, C 1-4  alkyl, C 1-4  alkoxy, S(O) k C 1-4  alkyl, S(O) 2 NR 8 R 9 , NHS(O) 2 (C 1-4  alkyl), NH 2 , NH(C 1-4  alkyl), N(C 1-4  alkyl) 2 , NHC(O)NH 2 , C(O)NH 2 , C(O)NH(C 1-4  alkyl), NHC(O)(C 1-4  alkyl), CO 2 H, CO 2 (C 1-4  alkyl), C(O)(C 1-4  alkyl), CF 3 , CHF 2 , CH 2 F, CH 2 CF 3  or OCF 3 .  
     
   
   
       2 . A compound as claimed in  claim 1  wherein L is CH.  
   
   
       3 . A compound as claimed in  claim 1  wherein M is N.  
   
   
       4 . A compound as claimed in  claim 1  wherein R 1  is phenyl (optionally substituted by halo, C 1-4  alkyl, C 1-4  alkoxy, CF 3 , or OCF 3 ), S(O) 2 (C 1-4  alkyl), S(O) 2 (C 1-4  fluoroalkyl), S(O) 2 phenyl (optionally substituted by halo, cyano, C 1-4  alkyl, C 1-4  alkoxy, CF 3 , OCF 3 , S(O) 2 (C 1-4  alkyl) or S(O) 2 (C 1-4  fluoroalkyl)), benzyl (optionally substituted by halo, C 1-4  alkyl, C 1-4  alkoxy, CF 3  or OCF 3 ), benzoyl (optionally substituted by halo, C 1-4  alkyl, C 1-4  alkoxy, CF 3  or OCF 3 ), C(O)NHphenyl (optionally substituted by halo, C 1-4  alkyl, C 1-4  alkoxy, CF 3 , or OCF 3 ), S(O) 2 thiophenyl, Ch 2 pyridinyl, CH 2 quinolinyl or CH 2 thiazolyl.  
   
   
       5 . A compound as claimed in  claim 1  wherein R 2  is phenyl optionally substituted by halo.  
   
   
       6 . A compound as claimed in  claim 1  wherein R 3  is hydrogen or methyl.  
   
   
       7 . A compound as claimed in  claim 1  wherein R 4  is ethyl.  
   
   
       8 . A compound as claimed in  claim 1  wherein R 5  is phenyl(C 1-2  )alkyl, phenyl(C 1-2  alkyl)NH, phenyl, heteroaryl or heteroaryl(C 1-2 )alkyl; wherein the phenyl and heteroaryl rings are optionally substituted by halo, cyano, nitro, hydroxy, C 1-4  alkyl, C 1-4  alkoxy, S(O) k C 1-4  alkyl, S(O) 2 NR 8 R 9 , NHS(O) 2 (C 1-4  alkyl), NH 2 , NH(C 1-4  alkyl), N(C 1-4  alkyl) 2 , NHC(O)NH 2 , C(O)NH 2 , C(O)NH)C 1-4  alkyl), NHC(O)(C 1-4  alkyl), CO 2 H, CO 2 (C 1-4  alkyl), C(O)(C 1-4  alkyl), CF 3 , CHF 2 , CH 2 F, CH 2 CF 3  of OCF 3 ; and R 8  and R 9  are, independently, hydrogen or C 1-4  alkyl, or together with a nitrogen or oxygen atom, may join to form a 5- or 6-membered ring which is optionally substituted with C 1-4  alkyl, C(O)H or C(O)(C 1-4  alkyl); and k is 0, 1 or 2.  
   
   
       9 . A process for preparing of a compound as claimed in  claim 1  comprising: 
 i. where L is N, reacting a compound of formula (II):                        with a compound of formula (III):                          in the presence of sodium iodide and a suitable base, in a suitable solvent;      ii. where L is CH, reacting a compound of formula (IV):                           with: 
 a) an acid of formula R 1 CO 2 H in the presence of a suitable coupling agent in the presence of a suitable base in a suitable solvent;  
 b) an acid chloride of formula R 1 C(O)Cl or sulphonyl chloride of formula R 1 S(O) 2 Cl, in the presence of a suitable base in a suitable solvent; or,  
 c) an aldehyde of formula R 1 CHO in the presence of NaBH(OAc) 3  (wherein AC is C(O)CH 3 ) and acetic acid, in a suitable solvent;  
   iii. coupling a compound of formula (V):                           with: 
 a) an acid of formula R 5 CO 2 H in the presence of a suitable coupling agent in the presence of a suitable base in a suitable solvent; or,  
 b) an acid chloride of formula R 5 C(O)Cl, in the presence of a suitable base in a suitable solvent.  
   
   
   
       10 . A pharmaceutical composition which comprises a compound as claimed in  claim 1 , or a pharmaceutically acceptable salt thereof or solvate thereof, and a pharmaceutically acceptable adjuvant, diluent or carrier.  
   
   
       11 - 12 . (canceled)  
   
   
       13 . A method of treating a CCR 5  mediated disease state comprising administering to a patient in need of such treatment an effective amount of a compound as claimed in  claim 1 , or a pharmaceutically acceptable salt thereof or solvate thereof.  
   
   
       14 . An intermediate of formula (V):  
     
       
         
         
             
             
         
       
       wherein L, M, R 1 , R 2 , R 3  and R 4  are as defined in  claim 1.